Tauriga Sciences Inc. Receives Additional $150,000 USD Private Placement Tranche from Tokyo Based Dragoon Capital, Inc.
SAN FRANCISCO, Dec. 24, 2014 /PRNewswire/ — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or “the Company”), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today announced that Tokyo, Japan based Dragoon Capital, Inc. (“Dragoon”) has invested an additional $150,000 USD of private placement capital into Tauriga. This additional $150,000 USD tranche was invested at a price of $0.0125 per share (Restricted) and there were no warrants offered in conjunction with this financing. To this date, Dragoon has now invested a total of $500,000 USD of private placement capital into Tauriga. The Company plans to use this additional capital to increase production of its TopiCanna brand of topical medicinal cannabis cream and establish a marketing campaign. The Company continues to work diligently toward the completion of the definitive distribution agreement with Japanese distributor iFLOW, Inc. (“iFLOW”). In anticipation of such agreement, the Company has been developing a TopiCanna product specific for the Japanese marketplace that incorporates CBD (Cannabidiol) from the stem of the plant (to comply with the laws and regulations of Japan).
Dragoon Capital Inc. CEO Shuichi Uda stated, “Our investment banking firm continues to believe strongly in the both the vision and business prospects of Tauriga Sciences, Inc. We are also excited at the prospects of Tauriga launching its TopiCanna product line in Japan and Asia, where we believe that the consumer demand has the potential to be substantial. Dragoon takes a long term approach at investing in companies and therefore is not concerned about the recent trading volatility in shares of Tauriga. Conversely, we are pleased with the improving fundamentals of the Company and plan to continue to support the Company financially, so that it may grow into a successful international business.”
About Tauriga Sciences, Inc.:
Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues in the natural wellness sector and in developing a proprietary synthetic biology platform technology. The mission of the Company is to acquire and build a balanced portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company’s business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. Please visit the Company’s corporate website at www.tauriga.com.
About Dragoon Capital, Inc.
Dragoon Capital Inc. is an independent investment banking firm that provides advice to institutional investors and middle-market and emerging growth companies in Japan and worldwide. Together, the firm’s management professionals have more than 80 years of experience providing private and public companies with a broad spectrum of investment banking and financial advisory services, including: mergers and acquisitions; equity and debt capital raises; and restructurings. The firm provides objective, unbiased, results-focused services that clients need to achieve their goals. For more information, please visit: https://www.dragoon.co.jp/en/index.html
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration. In addition the above mentioned investment banking agreement with Dragoon Capital is contractually on a best efforts basis.
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.
Food and Drug Administration Disclaimer: None of the statements contained in this press release regarding any of the products either offered or to be offered in the future by the Company have been evaluated by the Food and Drug Administration. Additionally, none of the products is intended to diagnose, treat, cure, or prevent any disease.
To view the original version on PR Newswire, visit:https://www.prnewswire.com/news-releases/tauriga-sciences-inc-receives-additional-150000-usd-private-placement-tranche-from-tokyo-based-dragoon-capital-inc-300013887.html
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | email@example.com